Search results
Powerful overall survival data. IMPACT: PROVENGE has been clinically proven to extend life for certain men with mCRPC. In IMPACT, the double-blind, placebo-controlled trial that supported FDA approval of PROVENGE, men with mCRPC (N=512) were randomly assigned in a 2:1 ratio to receive either sipuleucel-T (n=341) or placebo (n=171).
PROVENGE is a personalized immunotherapy for men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). PROVENGE is made by culturing a patient’s own immune cells with a recombinant protein that is prostate specific.
29 lip 2010 · To confirm these survival findings, we conducted a double-blind, placebo-controlled, multicenter trial, called the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) study,...
The median extended survival period for prostate cancer patients receiving docetaxel is 2.4 months, or an average cost of $16,667 per month of added survival. This cost does not take into consideration the serious AEs associated with docetaxel (neutropenia, infections, anemia, nausea, and vomiting).
12 kwi 2019 · Recent data support a greater relative and absolute improvement in overall survival in these men with mCRPC treated with sipuleucel-T based on lower pre-treatment PSA levels . Despite this ...
With a unique mechanism of action that leverages the adaptive immune response, PROVENGE provides a lasting immunological response for your patient with advanced prostate cancer. In a post hoc analysis of the IMPACT trial, data suggests that men who start PROVENGE with a lower PSA level live longer. 1,2
1 gru 2019 · PROCEED provides contemporary survival data for sipuleucel-T-treated men in a real-world setting of new life-prolonging agents, which will be useful in discussing treatment options with patients and in powering future trials with sipuleucel-T.
